Altheos, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://altheos.net
ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
Phase 2
Completed
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: ATS907
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Altheos, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01668524
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
Phase 1
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Stage 1 - ATS907 - Dose 2Drug: Stage 1 - ATS907 - Dose 1Drug: Stage 1 - ATS907 - Dose 4Drug: Stage 1 - VehicleDrug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1Drug: TimopticDrug: Stage 1 - ATS907 - Dose 3
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Altheos, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT01520116
© Copyright 2025. All Rights Reserved by MedPath